Atossa Therapeutics Issues Letter to Shareholders

January 9, 2024

https://www.globenewswire.com/news-release/2024/01/09/2806291/0/en/Atossa-Therapeutics-Issues-Letter-to-Shareholders.html

SEATTLE, Jan. 09, 2024 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announces the issuance of the following Letter to Shareholders from Steven Quay, M.D., Ph.D., the Company’s President and Chief Executive Officer:

Read more at globenewswire.com

Related news for (ATOS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.